Sinopharm Hyundai (642.SH): Ceftriaxone sodium for injection was approved for marketing in Germany.

gronhui announced on January 28th that its controlling grandson, DALIPharma GmbH (“DALI Pharma "), recently received the marketing license of ceftriaxone sodium for injection (25mg, 5mg and 1g) approved and issued by the German Federal Agency for Drugs and Medical Devices (BfArM).

indications: ceftriaxone sodium is a long-acting and broad-spectrum third-generation cephalosporin antibiotic, which is generally used to treat bacterial meningitis caused by sensitive bacteria, community and hospital-acquired pneumonia, acute otitis media, abdominal infection, complicated urinary tract infection (including pyelonephritis), bone and joint infection, skin and soft tissue infection, gonorrhea, syphilis and bacterial endocarditis.

this time, DALI Pharma's ceftriaxone sodium for injection (25mg, 5mg and 1g) was approved for marketing in Germany, which indicates that DALI Pharma has the qualification to sell the above products in the German market, which will have a positive impact on the company's expansion into the EU market, and the company will actively promote the marketing and sales of the above products in the EU market in the future.

this article is from gelonghui.